CELLBXHEALTH PLC Stock Price, News & Analysis

CelLBxHealth plc (trading in the United States as ANGLE PLC S/ADR under the symbol ANPCY) is described in regulatory news as a global precision circulating tumour cell (CTC) intelligence company. The business focuses on developing and commercialising CTC-based solutions that use a simple blood sample to support research, drug development and clinical oncology. Company announcements state that it has proposed and then adopted a change of name from ANGLE plc to CelLBxHealth plc, with the new name intended to reflect a sharpened focus on CTC intelligence and liquid biopsy.

According to multiple company releases, CelLBxHealth’s core technology is the patent-protected Parsortix® platform, also referred to as the Parsortix® PC1 System. This system is described as an FDA-cleared circulating tumour cell harvesting technology that enriches CTCs from peripheral blood using a microfluidic separation cassette based on cell size and deformability. The company states that Parsortix enables comprehensive downstream analysis of harvested cells, including whole-cell imaging, proteomic profiling, and full genomic and transcriptomic workflows. In some disclosures, the company notes that the standalone device does not itself identify or characterise CTCs and that any downstream assays require separate validation by the end user.

Company communications describe CelLBxHealth/ANGLE as a liquid biopsy specialist using CTCs obtained from blood samples as an alternative or complement to tissue biopsies and circulating tumour DNA (ctDNA). The firm highlights that CTC analysis can provide dynamic insights into tumour biology, disease progression and treatment response. In its own commentary, the company contrasts CTCs with ctDNA, noting that CTCs offer whole-cell information, including surface protein expression and cellular phenotype, which can be important for targeted therapies such as antibody-drug conjugates.

Business activities and commercial focus

Across several news releases, the company outlines its commercial activities in three main areas:

• Product sales: Sales of the Parsortix® platform with associated consumables and assays. The company has also described the Parsortix system workflow as being compatible with Illumina next-generation sequencing (NGS) cancer panels for dual analysis of CTC-derived DNA and ctDNA from a single blood sample.
• Laboratory and clinical services: Biopharma and clinical services delivered from GCLP-compliant or GCLP-certified laboratories in the UK. These services include custom assay development, clinical trial testing, clinical-trial support and bespoke service testing for pharmaceutical and biotechnology customers.
• Lab Developed Tests (LDTs) and validation work: Development of LDTs and Research Use Only validation of existing commercial proteomic and genomic assays on CTC samples, often in collaboration with partners.

In interim results and operational updates, the company reports that it has completed contracts with large pharmaceutical companies and is involved in collaborations with biopharma and medtech partners. Examples mentioned include work with Eisai and AstraZeneca on assays such as HER2, AR and DDR for oncology applications, an ongoing services agreement with Immatics across multiple clinical trials, and a collaboration with Myriad Genetics to transfer an existing tissue-based cancer test to a CTC-based sample using the Parsortix system. Company statements also refer to discussions with large pharma, large medtech and healthcare providers, as well as engagement with the UK National Health Service regarding potential clinical studies.

Technology and applications

CelLBxHealth emphasises that its technology is intended to support precision oncology by enabling detailed characterisation of CTCs. Company communications describe applications such as:

• Monitoring changes in biomarker status over time in metastatic cancer, for example tracking HER2 status in breast cancer patients.
• Supporting clinical trials by providing CTC enrichment and analysis across multiple studies, including late-stage trials in indications such as melanoma.
• Combining CTC-based analysis with established diagnostic workflows, such as Roche Tissue Diagnostics’ BenchMark ULTRA automated staining system, to assess targets like HER2, TROP2 and PSMA.
• Enabling research into difficult-to-monitor cancers, including glioblastoma, where company data presented at scientific meetings reported detection and characterisation of CTCs and extracellular vesicles using the Parsortix system and CellKeep™ slides.

In its own descriptions, the company notes that over one hundred peer-reviewed publications from numerous independent research centres have reported on the performance and use of the Parsortix system. It also highlights that expert consensus work in the European Journal of Cancer has identified CTCs as clinically relevant biomarkers and has cited the Parsortix platform as a promising next-generation technology for clinical applications.

Corporate evolution and branding

Regulatory news from 2025 explains that ANGLE plc proposed and then implemented a name change to CelLBxHealth plc. The company states that the new name reflects a revised strategy focused on CTC intelligence and high-value CTC-based precision diagnostic testing for pharmaceutical services and clinical diagnostics. The element “CelLBx” is described as referencing circulating tumour cells obtained via liquid biopsy, while the addition of “Health” is intended to underscore the aim of supporting pharmaceutical companies and clinicians in improving outcomes for cancer patients.

Announcements also describe changes in the company’s leadership structure, including the appointment of an Executive Chairman, subsequent board changes, and later the appointment of a Chief Executive Officer and additional non-executive directors. These changes are presented as part of a broader strategy to sharpen commercial focus, manage costs and pursue funding to extend the company’s cash runway.

Regulatory and market context

Company disclosures emphasise that the Parsortix® PC1 system has FDA clearance for specific intended use in enriching CTCs from peripheral blood of patients diagnosed with metastatic breast cancer, and that any diagnostic or prognostic claims must be based on separately validated downstream assays. Some releases carry the statement “For Research Use Only. Not for use in diagnostic procedures” in relation to certain products or studies, reflecting the distinction between research applications and regulated clinical use.

CelLBxHealth’s shares are referenced in announcements as trading on the AIM market of the London Stock Exchange under the ticker AGL prior to the name change, with the new AIM ticker indicated as CLBX. In the United States, the company is associated with the OTCQX symbol ANPCY as an ADR representation. The company’s communications also refer to challenging external conditions for pharma and medtech customers, including access to capital, policy volatility and tariff uncertainty, which can affect the timing of new contracts and revenue.

Research and scientific engagement

Scientific engagement is a recurring theme in company news. CelLBxHealth/ANGLE reports participation in international conferences focused on circulating tumour cells and antibody-drug conjugates, where it presents proof-of-concept data and workflow integrations. The company highlights that research enabled by the Parsortix system has been published in high-impact journals, including work in Nature Medicine that contributed to the creation of a spin-out company developing novel therapeutics targeting cancer metastasis.

In oncology-focused communications, the company underscores the potential of CTCs to provide real-time insight into tumour evolution and treatment response, particularly in metastatic disease. It also notes that expert consensus supports the view that CTC testing is likely to become part of routine clinical practice over time, and that CTCs can offer information not captured by ctDNA alone.

Summary

Overall, CelLBxHealth plc (formerly ANGLE plc), as described in its own regulatory and news announcements, positions itself as a specialist in CTC-based liquid biopsy technologies. Through the Parsortix® platform, associated consumables and assays, and GCLP-based service laboratories, the company aims to support pharmaceutical research, clinical trial programmes and the development of precision oncology approaches that rely on detailed analysis of circulating tumour cells from blood samples.